Syngene International Ltd. announces a leadership change

Immediate Non-Compliance Assessment

• Compliance Status: The resignation of Mr. Kush Parmar, effective at the close of business hours on July 29, 2026, does not result in immediate non-compliance under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ^[1]. Company filings confirm that the change complies with SEBI Listing Regulations ^[1].
• Committee Membership Impact: Mr. Parmar stepped down specifically from the Risk Management Committee and the Science and Technology Committee ^[1]. The official disclosure does not list him as a member of either the Audit Committee or the Nomination & Remuneration Committee (NRC) ^[1].
• Statutory Cure Mechanism: Under SEBI LODR, a mid-term vacancy of an Independent Director (ID) does not create an immediate regulatory breach on the effective date of resignation. The regulations explicitly provide a statutory cure period to appoint a successor and re-align committee compositions.

Statutory Timeline for Filling the Vacancy

• Independent Director Replacement Window: Under Regulation 25(6) of SEBI LODR Regulations, any vacancy in the office of an Independent Director must be filled by the listed entity at the earliest, and not later than 3 months from the date of such vacancy.
• Compliance Deadline: Grounded on the effective resignation date of July 29, 2026 ^[1], the statutory 3-month timeline requires Syngene International to complete the appointment of a replacement Independent Director on or before October 29, 2026.
• Committee Reconstitution: To the extent that board committee compositions (including the Risk Management Committee ^[1]) require re-balancing to meet minimum ID ratios, the mandatory reconstitution must be finalized within the same statutory timeframe.

Governance Context & Disclosure Limits

• Reason for Exit: The company reported that Mr. Parmar stepped down due to expanding commitments in the United States and his inability to devote sufficient time while residing outside India, confirming no other material reasons were present ^[1].
• Disclosure Gap: The overall post-resignation Independent Director count relative to total board strength, as well as the full constituent list of the Audit Committee and NRC, were not detailed in the retrieved event notification ^[1].

The supplied retrieval context does not contain the full text of the stock exchange disclosure for the Independent Director resignation, so whether the company explicitly confirmed the absence of material disagreements regarding financial reporting or internal controls cannot be verified from the available documents.

The available news filings note that Kush Parmar resigned as an Independent Director effective July 29, 2026, citing US-based commitments ^[1], but the specific compliance statements or disclosures mandated by SEBI LODR regulations are not detailed in the retrieved text.

Mr. Kush Parmar was a member of the Risk Management Committee and the Science and Technology Committee prior to his resignation as an Independent Director, effective at the close of business hours on July 29, 2026 ^[1].

Board Reallocation and Committee Continuity

• Committee Vacancies: With his departure, Mr. Parmar ceased his memberships on both the Risk Management Committee and the Science and Technology Committee ^[1].
• Board-Level Appointments: To address overall board composition and expertise following departures, the board appointed Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors ^[2].
• Disclosure Gap: Specific procedural details regarding how the exact responsibilities, quorums, and chairperson/member slots for the Risk Management and Science and Technology committees will be reallocated among incoming or existing directors are not explicitly detailed in the available disclosures.